C4 Therapeutics director acquires 4,618 shares

C4 Therapeutics, Inc. director Donna Roy Grogan acquired 4,618 shares of common stock on October 1, 2026, under the company’s Non-Employee Director Compensation Policy.

Rhea-AI Filing Summary

C4 Therapeutics, Inc. director Donna Roy Grogan acquired 4,618 shares of common stock on October 1, 2026, under the company’s Non-Employee Director Compensation Policy. She elected to receive shares in lieu of cash compensation for her director services. The reported price was $3.14 per share, based on the closing market price that day; her direct holdings following the transaction were 79,471 shares.

Insider Trade Summary

Grant/Award: 4,618 shares

Grant/Award 1 txn

Insider GROGAN DONNA ROY

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	4,618	$3.14	$15K

Holdings After Transaction: Common Stock — 79,471 shares (Direct)

Footnotes (2)

1. F1. These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
2. F2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2026.

Key Figures

Shares acquired: 4,618 shares Reported price per share: $3.14 per share Direct holdings following transaction: 79,471 shares

3 metrics

Shares acquired 4,618 shares October 1, 2026

Reported price per share $3.14 per share Based on the closing market price on October 1, 2026

Direct holdings following transaction 79,471 shares After the October 1, 2026 transaction

Key Terms

Non-Employee Director Compensation Policy, in lieu of cash compensation, closing market price

3 terms

Non-Employee Director Compensation Policy financial

"in accordance with the Issuer's Non-Employee Director Compensation Policy"

in lieu of cash compensation financial

"elected to receive shares ... in lieu of cash compensation"

closing market price market

"based upon the closing market price"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CCCC shares did director Donna Roy Grogan receive?

Donna Roy Grogan acquired 4,618 shares of C4 Therapeutics common stock on October 1, 2026. She elected to receive shares instead of cash compensation for her services as a non-employee director.

How was the reported CCCC share price determined?

The reported price of $3.14 per share was based on the closing market price of C4 Therapeutics common stock on October 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 04:44 PM Accepted by SEC EDGAR 10/02/2026 - 04:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GROGAN DONNA ROY

(Last) (First) (Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2026		A(1)		4,618	A	$3.14(2)	79,471	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2026.

Remarks:

	/s/ Shagha Russell, Attorney-in-Fact	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)